GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » 5-Year RORE %

AZTA (Azenta) 5-Year RORE % : -14.38% (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Azenta 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Azenta's 5-Year RORE % for the quarter that ended in Sep. 2024 was -14.38%.

The industry rank for Azenta's 5-Year RORE % or its related term are showing as below:

AZTA's 5-Year RORE % is ranked worse than
63.49% of 671 companies
in the Medical Devices & Instruments industry
Industry Median: -4.02 vs AZTA: -14.38

Azenta 5-Year RORE % Historical Data

The historical data trend for Azenta's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta 5-Year RORE % Chart

Azenta Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.46 6.58 72.81 -17.58 -14.38

Azenta Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.58 -18.09 -27.01 -27.70 -14.38

Competitive Comparison of Azenta's 5-Year RORE %

For the Medical Instruments & Supplies subindustry, Azenta's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azenta's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Azenta's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Azenta's 5-Year RORE % falls into.



Azenta 5-Year RORE % Calculation

Azenta's 5-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -2.97-0.88 )/( 27.67-0.9 )
=-3.85/26.77
=-14.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 5-year before.


Azenta  (NAS:AZTA) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Azenta 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Azenta's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Azenta Business Description

Traded in Other Exchanges
Address
200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.
Executives
Herman Cueto officer: EVP, Chief Financial Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes officer: VP, Chief Accounting Officer C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Ginger Zhou officer: SVP and General Manager, Genom 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jason Joseph officer: VP, General Counsel, Secretary 170 TRACER LANE, WALTHAM MA 02451
David C Gray officer: Chief Strategy & New Business C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin director
Dorothy E Puhy director DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne officer: SVP and GM, Life Sciences Proj 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus officer: EVP & Chief Operating Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson officer: EVP & Chief Financial Officer C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley officer: Chief Human Resources Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram officer: VP, Finance & Corp. Controller 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De officer: Chief Commercial Officer, LS 15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka officer: Sr. VP, General Manager 15 ELIZABETH DRIVE, CHELMSFORD MA 01824